miRNA-101 suppresses epithelial-to-mesenchymal transition by targeting HMGA2 in pancreatic cancer cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 4, 2016, Pages 432-439

  Jiang, Wenli ^a,b   Gu, Wen ^c   Qiu, Ronglin ^a,b   He, Songbing ^d   Shen, Chenglong ^c   Wu, Yaohao ^a,b   Zhang, Jie ^a,b   Zhou, Jiajia ^a,b   Guo, Yixing ^e   Wan, Daiwei ^f   Li, Zhixi ^a,b   Deng, Jiemin ^a,b   Zeng, Lexiang ^a,b   Tang, Jin ^a,b   Zhou, Jin ^g   Zhi, Qiaoming ^c   Deng, Xiaogeng ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WANNAN MEDICAL COLLEGE   (China)

^f UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^g CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Epithelial to mesenchymal transition; HMGA2; MiR 101; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA 101; MICRORNA; MIRN101 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BIOINFORMATICS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MTT ASSAY; OVERALL SURVIVAL; PANCREAS CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BIOLOGY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL CULTURE;

CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HMGA2 PROTEIN; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84961603788     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150507122142     Document Type: Article

References (36)

1. Yeo, T.P.; Lowenfels, A.B. Demographics and epidemiology of pancreatic cancer. Cancer J., 2012, 18, 477-484.
2. Chen, W.Q.; Liang, D.; Zhang, S.W.; Zheng, R.S.; He, Y.T., Pancreatic cancer incidence and mortality patterns in china, 2009. Asi. Pac. J. Cancer Prev., 2013, 14, 7321-7324.
3. Junfeng, Z.; Yingxue, H.; Peiwu, Y. Systematic review of risk factors for metastasis to para-aortic lymph nodes in gastric cancer. Surg. Oncol., 2013, 22, 210-216.
4. Huang, J.Y.; Xu, Y.Y.; Li, M.; Sun, Z.; Zhu, Z.; Song, Y.X.; Miao, Z.F.; Wu, J.H.; Xu, H.M. The prognostic impact of occult lymph node metastasis in node-negative gastric cancer, a systematic review and meta-analysis. Ann. Surg. Oncol., 2013, 20, 3927-3934.
5. Brabletz, T. EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell, 2012, 22, 699-701.
6. Fan, Y.L.; Zheng, M.; Tang, Y.L.; Liang, X. H. A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol. Lett., 2013, 6, 1174-1180.
7. Al Saleh, S.; Sharaf, L.H.; Luqmani, Y.A., Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int. J. Oncol., 2011, 38, 1197-1217.
8. Steinestel, K.; Eder, S.; Schrader, A.J.; Steinestel, J. Clinical significance of epithelial-mesenchymal transition. Clin. Transl. Med., 2014, 3, 17.
9. Hu, Y.; Tang, H., MicroRNAs regulate the epithelial to mesenchymal transition (EMT) in cancer progression. Microrna, 2014, 3(2),108-117.
10. Piccinini, A.M.; Midwood, K.S., Illustrating the interplay between the extracellular matrix and microRNAs. Int. J. Exp. Pathol., 2014, 95, 158-180.
11. Ahmad, N.; Haider, S.; Jagannathan, S.; Anaissie, E.; Driscoll, J.J. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia, 2014, 28, 732-738.
12. Gargalionis, A.N.; Basdra, E.K. Insights in microRNAs biology. Curr. Top. Med. Chem., 2013, 13, 1493-1502.
13. Paterson, E.L.; Kazenwadel, J.; Bert, A.G.; Khew-Goodall, Y.; Ruszkiewicz, A.; Goodall, G.J. Down-regulation of the miRNA- 200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia, 2013, 15, 180-191.
14. Schee, K.; Boye, K.; Abrahamsen, T.W.; Fodstad, O.; Flatmark, K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR- 101, miR-106a and miR-145 in colorectal cancer. BMC Cancer, 2012, 12, 505.
15. He, X.P.; Shao, Y.; Li, X.L.; Xu, W.; Chen, G.S.; Sun, H.H.; Xu, H.C.; Xu, X.; Tang, D.; Zheng, X.F.; Xue, Y.P.; Huang, G.C.; Sun, W.H. Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J., 2012, 279, 4201-4212.
16. Luo, L.; Zhang, T.; Liu, H.; Lv, T.; Yuan, D.; Yao, Y.; Lv, Y.; Song, Y. MiR-101 and Mcl-1 in non-small-cell lung cancer, expression profile and clinical significance. Med. Oncol., 2012, 29, 1681-1686.
17. Lin, C.; Huang, F.; Zhang, Y.J.; Tuokan, T.; Kuerban, G., Roles of MiR-101 and its target gene Cox-2 in early diagnosis of cervical cancer in Uygur women. Asi. Pac. J. Cancer Prev., 2014, 15, 45-48.
18. Xu, Y.; An, Y.; Wang, Y.; Zhang, C.; Zhang, H.; Huang, C.; Jiang, H.; Wang, X.; Li, X. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol. Rep., 2013, 29, 2019-2024.
19. Strillacci, A.; Valerii, M.C.; Sansone, P.; Caggiano, C.; Sgromo, A.; Vittori, L.; Fiorentino, M.; Poggioli, G.; Rizzello, F.; Campieri, M.; Spisni, E., Loss of miR-101 expression promotes Wnt/betacatenin signalling pathway activation and malignancy in colon cancer cells. J. Pathol., 2013, 229, 379-389.
20. Boreddy, S.R.; Srivastava, S.K. Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-tomesenchymal transition in an orthotopic model. Oncogene, 2013, 32, 3980-3991.
21. Ponnusamy, M.P.; Lakshmanan, I.; Jain, M.; Das, S.; Chakraborty, S.; Dey, P.; Batra, S.K. MUC4 mucin-induced epithelial to mesenchymal transition: A novel mechanism for metastasis of human ovarian cancer cells. Oncogene, 2010, 29, 5741-5754.
22. Chen, C.L.; Chou, K.J.; Lee, P.T.; Chen, Y.S.; Chang, T.Y.; Hsu, C.Y.; Huang, W.C.; Chung, H.M.; Fang, H.C., Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines. Exp. Cell Res., 2010, 316, 1109-1118.
23. Dong, P.; Kaneuchi, M.; Watari, H.; Hamada, J.; Sudo, S.; Ju, J.; Sakuragi, N. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI- 1. Mol. Cancer, 2011, 10, 99.
24. Hung, C.S.; Liu, H.H.; Liu, J.J.; Yeh, C.T.; Chang, T.C.; Wu, C.H.; Ho, Y.S.; Wei, P.L.; Chang, Y.J., MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann. Surg. Oncol., 2013, 20 Suppl 3, S360-368.
25. Diaz-Lopez, A.; Moreno-Bueno, G.; Cano, A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag. Res., 2014, 6, 205-216.
26. Zhang, G.; Zhou, H.; Xiao, H.; Liu, Z.; Tian, H.; Zhou, T. MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig. Dis. Sci., 2014, 59, 98-107.
27. Zhang, J.P.; Zeng, C.; Xu, L.; Gong, J.; Fang, J.H.; Zhuang, S.M. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene, 2014, 33, 4069-4076.
28. Smits, M.; Nilsson, J.; Mir, S.E.; Van der Stoop, P.M.; Hulleman, E.; Niers, J.M.; De Witt Hamer, P.C.; Marquez, V.E.; Cloos, J.; Krichevsky, A.M.; Noske, D.P.; Tannous, B.A.; Wurdinger, T. miR-101 is down-regulated in glioblastoma resulting in EZH2- induced proliferation, migration, and angiogenesis. Oncotarget, 2010, 1, 710-720.
29. Li, Y.; Zhao, Z.; Xu, C.; Zhou, Z.; Zhu, Z.; You, T. HMGA2 induces transcription factor Slug expression to promote epithelialto- mesenchymal transition and contributes to colon cancer progression. Cancer Lett., 2014, 355, 130-140.
30. Fedele, M.; Palmieri, D.; Fusco, A. HMGA2: A pituitary tumour subtype-specific oncogene? Mol. Cell Endocrinol., 2010, 326, 19-24.
31. Ashar, H. R.; Chouinard, R.A.; Dokur, M.; Chada, K., In vivo modulation of HMGA2 expression. Biochim. Biophys. Acta, 2010, 1799, 55-61.
32. Zha, L.; Zhang, J.; Tang, W.; Zhang, N.; He, M.; Guo, Y.; Wang, Z., HMGA2 elicits EMT by activating the Wnt/beta-catenin pathway in gastric cancer. Dig. Dis. Sci., 2013, 58, 724-733.
33. Rizzi, C.; Cataldi, P.; Iop, A.; Isola, M.; Sgarra, R.; Manfioletti, G.; Giancotti, V. The expression of the high-mobility group A2 protein in colorectal cancer and surrounding fibroblasts is linked to tumor invasiveness. Hum. Pathol., 2013, 44, 122-132.
34. Fabjani, G.; Tong, D.; Wolf, A.; Roka, S.; Leodolter, S.; Hoecker, P.; Fischer, M.B.; Jakesz, R.; Zeillinger, R., HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol. Rep., 2005, 14, 737-741.
35. Luo, Y.; Li, W.; Liao, H. HMGA2 induces epithelial-tomesenchymal transition in human hepatocellular carcinoma cells. Oncol. Lett., 2013, 5, 1353-1356.
36. Liu, Q.; Zheng, S.; Gao, X.; Lu, M.; Sheyhidin, I.; Lu, X. HMGA2 is down-regulated by microRNA let-7 and associated with epithelial-mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs. Histopathology, 2014, 65, 408-417.